CAR-T cell therapy: current limitations and potential strategies
RC Sterner, RM Sterner - Blood cancer journal, 2021 - nature.com
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer
treatment. Although treatment with CAR-T cells has produced remarkable clinical responses …
treatment. Although treatment with CAR-T cells has produced remarkable clinical responses …
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Y Gong, RGJ Klein Wolterink, J Wang, GMJ Bos… - Journal of hematology & …, 2021 - Springer
Due to their efficient recognition and lysis of malignant cells, natural killer (NK) cells are
considered as specialized immune cells that can be genetically modified to obtain capable …
considered as specialized immune cells that can be genetically modified to obtain capable …
[HTML][HTML] Current progress in CAR-T cell therapy for solid tumors
Cancer immunotherapy by chimeric antigen receptor-modified T (CAR-T) cells has shown
exhilarative clinical efficacy for hematological malignancies. Recently two CAR-T cell based …
exhilarative clinical efficacy for hematological malignancies. Recently two CAR-T cell based …
[HTML][HTML] CAR-T design: Elements and their synergistic function
J Jayaraman, MP Mellody, AJ Hou, RP Desai… - …, 2020 - thelancet.com
Chimeric antigen receptor (CAR) T cells use re-engineered cell surface receptors to
specifically bind to and lyse oncogenic cells. Two clinically approved CAR-T–cell therapies …
specifically bind to and lyse oncogenic cells. Two clinically approved CAR-T–cell therapies …
Engineering and design of chimeric antigen receptors
T cells engineered with chimeric antigen receptors (CARs) have emerged as a potent new
class of therapeutics for cancer, based on their remarkable potency in blood cancers. Since …
class of therapeutics for cancer, based on their remarkable potency in blood cancers. Since …
CAR T cell therapy for solid tumors
K Newick, S O'Brien, E Moon… - Annual review of …, 2017 - annualreviews.org
The field of cancer immunotherapy has been re-energized by the application of chimeric
antigen receptor (CAR) T cell therapy in cancers. These CAR T cells are engineered to …
antigen receptor (CAR) T cell therapy in cancers. These CAR T cells are engineered to …
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance
ID Ferguson, B Patiño-Escobar, ST Tuomivaara… - Nature …, 2022 - nature.com
The myeloma surface proteome (surfaceome) determines tumor interaction with the
microenvironment and serves as an emerging arena for therapeutic development. Here, we …
microenvironment and serves as an emerging arena for therapeutic development. Here, we …
Size-dependent activation of CAR-T cells
As the targets of chimeric antigen receptor (CAR)–T cells expand to a variety of cancers,
autoimmune diseases, viral infections, and fibrosis, there is an increasing demand for …
autoimmune diseases, viral infections, and fibrosis, there is an increasing demand for …
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
Chimeric antigen receptor (CAR) T cell therapy has shown limited efficacy for the
management of solid tumor malignancies. In ovarian cancer, this is in part due to an …
management of solid tumor malignancies. In ovarian cancer, this is in part due to an …